Seeking Alpha / - 1 hour from now
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule
Seeking Alpha / - 1 hour from now
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx...
Seeking Alpha / - 59 minutes from now
(Alta, Norway 18 September 2025) Statkraft has submitted a license application for an upgrade of the Alta power plant. By utilizing water currently bypassing the plant during floods, production could increase by up to 20 percent. This will be achieved by installing a third turbine, with minimal new...
Seeking Alpha / - 59 minutes from now
(Alta, 18. september 2025) Statkraft har søkt konsesjon for en oppgradering av Alta kraftverk. Ved å produsere strøm på vannet som i dag tappes forbi kraftverket i flomperioder kan produksjonen øke inntil 20 prosent. Dette gjøres ved å installere en tredje turbin, et tiltak som er vurdert å gi mini...
Seeking Alpha / - 59 minutes from now
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform
Seeking Alpha / - 59 minutes from now
Bowman is providing planning and design services for the redevelopment of a container yard at Barbours Cut Terminal in the Port of Houston.
Seeking Alpha / - 59 minutes from now
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran...
Seeking Alpha / - 59 minutes from now
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients
Seeking Alpha / - 59 minutes from now
Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy
Seeking Alpha / - 59 minutes from now
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session
Seeking Alpha / - 59 minutes from now
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effe...
Seeking Alpha / - 59 minutes from now
New appointments further position Anterix to scale private broadband innovation for critical industries New appointments further position Anterix to scale private broadband innovation for critical industries
Seeking Alpha / - 59 minutes from now
Second acquisition under Digital Asset Treasury strategy positions Caliber alongside Chainlink’s infrastructure-first vision and marks the beginning of a growing LINK treasury Second acquisition under Digital Asset Treasury strategy positions Caliber alongside Chainlink’s infrastructure-first vision...
Seeking Alpha / - 59 minutes from now
ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first li...
Seeking Alpha / - 49 minutes from now
Summary